Cytek Biosciences

A U.S. court ruled in a patent dispute against Cytek Biosciences that three of four patent claims were not infringed and are invalid, but found infringement under the doctrine of equivalents for the fourth claim. The court awarded $56 million in damages, including $20 million for lost profits and $36 million for royalties. Cytek said it will appeal the decision and the damages award, and emphasized that the judgment does not require any changes to its products or business operations. » More on de.investing.com

Cytek Biosciences reported Q1 2026 revenue of $44.1 million (up 6% year‑over‑year) and saw strong growth of 32% in the U.S. Earnings per share were a loss of $0.15, missing the forecast of -$0.10; operating expenses rose 13% due to higher legal and administrative costs. The stock fell 6.68% in after‑hours trading. The company maintains revenue guidance of around $208 million for 2026 and $224.95 million for 2027 and emphasizes investments in products such as the Aurora Evo system. » More on de.investing.com

Cytek Biosciences reported revenue of USD 201.5 million for 2025, up 1% and thus outperforming the flow cytometry market (-4%). Recurring revenue rose to 34%; new products such as Aurora Evo and Muse Micro, expansion in APAC and a new manufacturing site in Singapore contributed to the growth. The cash position of USD 261.5 million provides room for acquisitions and share buybacks. For 2026, Cytek expects strong growth in the services and reagents segments and plans to expand its clinical business in Europe and China. » More on de.investing.com

Cytek Biosciences reported record revenue of $62.1 million (+8%) in the fourth quarter of 2025 with EPS of -$0.34, well below the expected -$0.02. Strong demand in EMEA and APAC and the expansion of product and bioinformatics offerings contributed to revenue growth, while higher operating costs and an impairment weighed on profitability. The stock rose 2.52% in after-hours trading; management forecasts continued revenue growth and plans to focus on higher‑margin product lines and expand bioinformatics and reagents. » More on de.investing.com

At the Morgan Stanley Global Healthcare Conference, Cytek Biosciences presented the new Aurora Evo instrument and plans regional manufacturing to strengthen its market presence. Sales of Full Spectrum Profiling instruments recently rose 3%, revenues from reagents and services each grew 18% in the second quarter, and Cytek Cloud has over 20,000 users. The company maintains a full-year forecast of -2% to +2% and reports EBITDA margins of around 7%; clinical approvals and partnerships are expected to further support growth. » More on de.investing.com